Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials.

Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC.

BMJ. 2008 Mar 22;336(7645):645-51. doi: 10.1136/bmj.39472.580984.AE. Epub 2008 Feb 25. Review. Erratum in: BMJ. 2009;339:b2951.

2.

HMG CoA reductase inhibitors (statins) for kidney transplant recipients.

Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF.

Cochrane Database Syst Rev. 2014 Jan 28;(1):CD005019. doi: 10.1002/14651858.CD005019.pub4. Review.

PMID:
24470059
3.

HMG CoA reductase inhibitors (statins) for kidney transplant recipients.

Navaneethan SD, Perkovic V, Johnson DW, Nigwekar SU, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD005019. doi: 10.1002/14651858.CD005019.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;1:CD005019.

PMID:
19370615
4.

HMG CoA reductase inhibitors (statins) for dialysis patients.

Navaneethan SD, Nigwekar SU, Perkovic V, Johnson DW, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD004289. doi: 10.1002/14651858.CD004289.pub4. Review.

PMID:
19588351
5.

HMG CoA reductase inhibitors (statins) for dialysis patients.

Navaneethan SD, Nigwekar SU, Perkovic V, Johnson DW, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD004289. doi: 10.1002/14651858.CD004289.pub3. Review. Update in: Cochrane Database Syst Rev. 2009;(3):CD004289.

PMID:
19370598
6.

HMG CoA reductase inhibitors (statins) for dialysis patients.

Navaneethan SD, Shrivastava R.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004289. Review. Update in: Cochrane Database Syst Rev. 2009;(2):CD004289.

PMID:
15495097
7.

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, Strippoli GF.

Cochrane Database Syst Rev. 2014 May 31;(5):CD007784. doi: 10.1002/14651858.CD007784.pub2. Review.

PMID:
24880031
8.

HMG CoA reductase inhibitors (statins) for dialysis patients.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Nigwekar SU, Hegbrant J, Strippoli GF.

Cochrane Database Syst Rev. 2013 Sep 11;(9):CD004289. doi: 10.1002/14651858.CD004289.pub5. Review.

PMID:
24022428
9.

Antioxidants for chronic kidney disease.

Jun M, Venkataraman V, Razavian M, Cooper B, Zoungas S, Ninomiya T, Webster AC, Perkovic V.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD008176. doi: 10.1002/14651858.CD008176.pub2. Review.

PMID:
23076940
10.

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.

Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007784. doi: 10.1002/14651858.CD007784. Review. Update in: Cochrane Database Syst Rev. 2014;5:CD007784.

PMID:
19370693
11.

Statins for improving renal outcomes: a meta-analysis.

Sandhu S, Wiebe N, Fried LF, Tonelli M.

J Am Soc Nephrol. 2006 Jul;17(7):2006-16. Epub 2006 Jun 8. Review.

12.

Statins for treatment of dyslipidemia in chronic kidney disease.

Shurraw S, Tonelli M.

Perit Dial Int. 2006 Sep-Oct;26(5):523-39. Review.

PMID:
16973506
13.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

14.
15.

Meta-analysis: the effect of statins on albuminuria.

Douglas K, O'Malley PG, Jackson JL.

Ann Intern Med. 2006 Jul 18;145(2):117-24. Review.

PMID:
16847294
16.

Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials.

Zhang X, Xiang C, Zhou YH, Jiang A, Qin YY, He J.

BMC Cardiovasc Disord. 2014 Feb 17;14:19. doi: 10.1186/1471-2261-14-19. Review.

17.

Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis.

Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF.

Ann Intern Med. 2012 Aug 21;157(4):263-75. doi: 10.7326/0003-4819-157-4-201208210-00007. Review.

18.

Statins for the primary prevention of cardiovascular disease.

Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S.

Cochrane Database Syst Rev. 2011 Jan 19;(1):CD004816. doi: 10.1002/14651858.CD004816.pub4. Review. Update in: Cochrane Database Syst Rev. 2013;1:CD004816.

19.

Effects of fibrates in kidney disease: a systematic review and meta-analysis.

Jun M, Zhu B, Tonelli M, Jardine MJ, Patel A, Neal B, Liyanage T, Keech A, Cass A, Perkovic V.

J Am Coll Cardiol. 2012 Nov 13;60(20):2061-71. doi: 10.1016/j.jacc.2012.07.049. Epub 2012 Oct 17. Review.

20.

Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.

Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, Cass A, Zhang H, Wang H.

Eur Heart J. 2013 Jun;34(24):1807-17. doi: 10.1093/eurheartj/eht065. Epub 2013 Mar 6. Review.

PMID:
23470492

Supplemental Content

Support Center